Class Action Filed Against GSK plc (GSK) - April 7, 2025 Deadline to Join - Contact Levi & Korsinsky
Portfolio Pulse from
A class action securities lawsuit has been filed against GlaxoSmithKline (GSK) alleging securities fraud between February 2020 and August 2022. The lawsuit claims GSK misled investors about the Zantac drug's potential cancer risks and the source of NDMA contamination, despite allegedly knowing about the issue for decades.
March 21, 2025 | 3:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
The class action lawsuit alleges GSK misrepresented information about Zantac's safety and NDMA contamination, which could negatively impact investor confidence and stock performance.
The lawsuit alleges significant misrepresentations by GSK management about Zantac's safety, which could lead to potential financial penalties, reputational damage, and reduced investor trust.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100